Alinity m HR HPV
Abbott Molecular, Inc. · Decision date Sep 10, 2025
What did the FDA approve?
FDA records P230003/S006 as a supplement to PMA P230003, with the supplement type “Panel Track”. The recorded decision is approval, dated Sep 10, 2025.
FDA approval order statement
Alinity m HR HPV is a qualitative in vitro test for the detection of Human Papillomavirus DNA. Cervical specimens should be collected by a health care professional using an endocervical collection brush/spatula placed in ThinPrep PreservCyt Solution or endocervical broom placed in SurePath Preservative Fluid.Self-collected vaginal specimens, obtained in a healthcare setting, can be tested as an alternative specimen type when cervical sampling is either contraindicated or cervical specimens otherwise cannot be obtained.This test identifies high-risk (HR) HPV types 16, 18, 45, while reporting the concurrent detection of the other HR genotypes (31/33/52/58) and (35/39/51/56/59/66/68).Alinity m HR HPV is indicated for use in routine cervical cancer screening as per professional medical guidelines, including triage of ASC-US cytology, co-testing (adjunctive screening) with cytology, and HPV primary screening of women to assess the risk for cervical pre-cancer and cancer. Patients should be followed-up in accordance with professional medical guidelines, results from prior screening, medical history, andother risk factors.
- Regulatory pathway
- PMA supplement
- Supplement type
- Panel Track
- Clinical specialty
- Microbiology
- Decision date
- Sep 10, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P230003/S006
- Regulatory pathway
- PMA supplement
- Applicant
- Abbott Molecular, Inc.
- Product code
- MAQ
- Decision code
- APPR
- Decision date
- Sep 10, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS.
- Applicant
- Abbott Molecular, Inc.
- Product code
- MAQ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230003. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230003 · Original PMA
Alinity m HR HPV
P230003/S006 received
Application receipt date recorded by FDA.
P230003/S006 · FDA decision
Panel Track
P230003/S008 · Related supplement
Alinity m HR HPV
P230003/S009 · Related supplement
Alinity m HR HPV
P230003/S010 · Related supplement
Alinity m HR HPV
P230003/S012 · Related supplement
Alinity m HR HPV
P230003/S011 · Related supplement
Alinity m HR HPV
P230003/S013 · Related supplement
Alinity m HR HPV
P230003/S016 · Related supplement
Alinity m HR HPV
P230003/S017 · Related supplement
Alinity m HR HPV
P230003/S014 · Related supplement
Alinity m HR HPV Assay
P230003/S018 · Related supplement
Alinity m HR HPV
P230003/S015 · Related supplement
Alinity m HR HPV
P230003/S019 · Related supplement
Alinity m HR HPV
Timeline entries are records held by MedtechLedger for P230003. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230003
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Alinity m HR HPVP230003 | Abbott Molecular, Inc. | PMA approval | Nov 1, 2023 | FDA |
Alinity m HR HPVP230003/S008 | Abbott Molecular, Inc. | PMA supplement | Sep 24, 2025 | FDA |
Alinity m HR HPVP230003/S009 | Abbott Molecular, Inc. | PMA supplement | Oct 17, 2025 | FDA |
Alinity m HR HPVP230003/S010 | Abbott Molecular, Inc. | PMA supplement | Jan 6, 2026 | FDA |
Alinity m HR HPVP230003/S012 | Abbott Molecular, Inc. | PMA supplement | Feb 24, 2026 | FDA |
Alinity m HR HPVP230003/S011 | Abbott Molecular, Inc. | PMA supplement | Mar 12, 2026 | FDA |
Alinity m HR HPVP230003/S013 | Abbott Molecular, Inc. | PMA supplement | May 15, 2026 | FDA |
Alinity m HR HPVP230003/S016 | Abbott Molecular, Inc. | PMA supplement | May 19, 2026 | FDA |
Alinity m HR HPVP230003/S017 | Abbott Molecular, Inc. | PMA supplement | May 28, 2026 | FDA |
Alinity m HR HPV AssayP230003/S014 | Abbott Molecular, Inc. | PMA supplement | Jun 8, 2026 | FDA |
Alinity m HR HPVP230003/S018 | Abbott Molecular, Inc. | PMA supplement | Jun 22, 2026 | FDA |
Alinity m HR HPVP230003/S015 | Abbott Molecular, Inc. | PMA supplement | Jul 23, 2026 | FDA |
Alinity m HR HPVP230003/S019 | Abbott Molecular, Inc. | PMA supplement | Sep 2, 2026 | FDA |
Explore the linked device profile
Other records with product code MAQ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
cobas HPVP100020/S066 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
cobas HPVP190028/S026 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
| Becton Dickinson and Company | PMA supplement | Aug 19, 2026 | FDA | |
BD Onclarity HPV AssayP160037/S028 | Becton Dickinson and Company | PMA supplement | Aug 14, 2026 | FDA |
cobas HPVP190028/S023 | Roche Molecular Systems, Inc. | PMA supplement | Jun 16, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Molecular, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1300 E Touhy Ave., Des Plaines, IL, 60018
Sources and methodology
- Original FDA record: P230003/S006
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records






